Lyell Immunopharma
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $34 | $13 | $3 | $13 |
Gross Profit | 34 | -4,888 | -5,021 | -5,044 |
EBITDA | -45,825 | -46,627 | -50,551 | -54,014 |
EBIT | -50,505 | -51,528 | -55,575 | -59,071 |
Net Income | -44,583 | -45,809 | -60,667 | -52,930 |
Net Change In Cash | 34 | 13 | 3 | 13 |
Free Cash Flow | -35,101 | -38,425 | -42,046 | -40,660 |
Cash | 100,299 | 133,424 | 125,650 | 145,647 |
Basic Shares | 256,309 | 255,398 | 254,252 | 253,085 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $130 | $84,683 | $10,650 | $7,756 |
Gross Profit | 130 | 68,216 | -3,885 | 281 |
EBITDA | -226,758 | -166,651 | -199,942 | -207,643 |
EBIT | -247,008 | -183,117 | -214,477 | -215,118 |
Net Income | -234,632 | -4,754 | -285,501 | -198,533 |
Net Change In Cash | 130 | 84,683 | 10,650 | 7,756 |
Cost of Revenue | 153,422 | |||
Free Cash Flow | -166,380 | -193,831 | -191,753 | -212,355 |
Cash | 145,647 | 123,554 | 293,828 | 140,406 |
Basic Shares | 250,983 | 247,080 | 242,738 | 246,579 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.17 |
2024-06-30 | -$0.18 |
2024-03-31 | -$0.15 |
2023-12-31 | -$0.20 |
